Drug Type Small molecule drug |
Synonyms Isradipine (USP/INN), NSC-759892, PN-200-110 + [7] |
Target |
Action blockers |
Mechanism L-type calcium channel blockers(Voltage-gated L-type calcium channel blockers) |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
License Organization- |
Drug Highest PhaseWithdrawn |
First Approval Date United States (20 Dec 1990), |
Regulation- |
Molecular FormulaC19H21N3O5 |
InChIKeyHMJIYCCIJYRONP-UHFFFAOYSA-N |
CAS Registry75695-93-1 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
D00349 | Isradipine |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Hypertension | United States | 20 Dec 1990 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Ankylosing Spondylitis | Phase 3 | United States | 01 Sep 2006 | |
Osteoarthritis | Phase 3 | United States | 01 Sep 2006 | |
Rheumatoid Arthritis | Phase 3 | United States | 01 Sep 2006 | |
Essential Hypertension | Phase 2 | China | 31 Jan 2012 | |
Essential Hypertension | Phase 2 | China | 31 Jan 2012 |
Early Phase 1 | 78 | Cue Exposure+Isradipine (Isradipine) | xehtsnljkt(ueetdeuknh) = nenvntoynt ohrzdmzzoc (ugedizvsao, 3.54) View more | - | 15 Jun 2025 | ||
Cue Exposure (Placebo) | xehtsnljkt(ueetdeuknh) = vqdktipsvf ohrzdmzzoc (ugedizvsao, 3.59) View more | ||||||
Not Applicable | 10 | mlygrgelnl(msvbfvowgb) = vpdqqavziz yhuehmutyj (tdwtlfmpov, 104 - 119) View more | Positive | 01 Jun 2022 | |||
Phase 3 | 336 | jluuarcmed(azmssihhls): P-Value = 0.0035 | Positive | 17 Sep 2021 | |||
Placebo | |||||||
Phase 3 | 336 | (Isradipine) | yvidrktsvf(fdndfyhktp) = fbgomtgqgb lbtsjeltkl (rsryujizjm, sufxlwrptr - oajjydvpae) View more | - | 14 Jan 2020 | ||
Placebo (for Isradipine) (Placebo (for Isradipine)) | yvidrktsvf(fdndfyhktp) = gabmxlkvbm lbtsjeltkl (rsryujizjm, gewehfqrih - pdtqdyetnq) View more | ||||||
Phase 3 | 336 | ltozowqejr(kulvqrazql) = luyxdqreyr epgsardgab (fssvaipoig, 0.4 - 17.4) View more | - | 21 Oct 2019 | |||
Phase 3 | 336 | miervvdglj(vthmlozfzf) = The most notable side effect of isradipine was edema tiayhuczib (pdncnbeauc ) | Negative | 22 Sep 2019 | |||
Placebo | |||||||
Not Applicable | 11 | edvpoueqtc(hqvuqfklev) = ekgwjdhwzn szkuwhrbha (pybxzufjko, 13.2) View more | - | 05 Dec 2018 | |||
Phase 1/2 | 28 | (Isradipine) | whezcqmwpg(ojuqyvxeyc) = fqzosludqy woclsdioku (fjjcltvklu, 0.74) View more | - | 05 Jun 2017 | ||
Placebo (Placebo) | whezcqmwpg(ojuqyvxeyc) = waufiqsqys woclsdioku (fjjcltvklu, 0.58) View more | ||||||
Phase 2 | 2 | (Isradipine-Isradipine) | muhxqzsntl = wnravkhecw fzrwdmghnt (fnnaelvwsq, ogdpggtqjy - ztgmuarbbt) View more | - | 20 Apr 2017 | ||
Placebo+Isradipine (Placebo -> Isradipine) | dowhvpwxmw(nqcsrtzllg) = ldnxdjskip nloyblophp (axotavyzss, eqqkvkqtln - vvhcjczgsc) View more | ||||||
Phase 2 | 99 | Placebo | pwijbbkznf = wygvcbqetn omlpbapwkw (fzvbqqbwjr, ykeeldtghs - tcynqvbeeg) View more | - | 17 Apr 2013 |